Detalles de la búsqueda
1.
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Ann Hematol
; 92(8): 1049-56, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23572137
2.
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Blood Cancer J
; 13(1): 93, 2023 06 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37336890
3.
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Blood Adv
; 4(18): 4267-4277, 2020 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32915972
4.
Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile.
Bone Marrow Transplant
; 55(11): 2188-2192, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32346077
5.
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.
Leuk Res
; 28(10): 1057-67, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15289018
6.
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
Eur J Cancer
; 49(15): 3242-6, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23876833
Resultados
1 -
6
de 6
1
Próxima >
>>